BrightGene Bio Medical Technology C (688166) — Free Cash Flow Generation Index
BrightGene Bio Medical Technology C (688166) has a Free Cash Flow Generation Index of -1.55x as of June 2023. Free cash flow of CN¥-41.35 Million represents -2% of operating cash flow (CN¥26.70 Million). See BrightGene Bio Medical Technology C (688166) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
BrightGene Bio Medical Technology C Free Cash Flow Generation Index (2016–2024)
Historical FCF Generation Index trend for BrightGene Bio Medical Technology C across 9 annual periods. Explore BrightGene Bio Medical Technology C debt service capacity to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for BrightGene Bio Medical Technology C (2016–2024)
Year-by-year Free Cash Flow Generation Index for BrightGene Bio Medical Technology C. For the full company profile including market capitalisation, see BrightGene Bio Medical Technology C (688166) market capitalisation.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.05x | CN¥-11.64 Million | CN¥245.56 Million | CN¥257.20 Million | ▲ +95.0% |
| 2023 | -0.95x | CN¥-185.08 Million | CN¥194.77 Million | CN¥389.33 Million | ▲ +28.8% |
| 2022 | -1.33x | CN¥-415.47 Million | CN¥311.26 Million | CN¥726.73 Million | ▲ +68.0% |
| 2021 | -4.17x | CN¥-733.59 Million | CN¥176.08 Million | CN¥909.66 Million | ▼ -224.0% |
| 2020 | -1.29x | CN¥-199.84 Million | CN¥155.43 Million | CN¥355.27 Million | ▼ -179.6% |
| 2019 | -0.46x | CN¥-28.21 Million | CN¥61.33 Million | CN¥89.54 Million | ▲ +39.3% |
| 2018 | -0.76x | CN¥-48.49 Million | CN¥63.99 Million | CN¥112.47 Million | ▲ +43.5% |
| 2017 | -1.34x | CN¥-47.94 Million | CN¥35.77 Million | CN¥83.70 Million | ▼ -160.1% |
| 2016 | 2.23x | CN¥66.31 Million | CN¥29.73 Million | CN¥36.58 Million | — |